Cargando…
Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease
BACKGROUND: There are no effective treatments or validated clinical response markers in systemic sclerosis (SSc). We assessed imaging biomarkers and performed gene expression profiling in a single-arm open-label clinical trial of tyrosine kinase inhibitor dasatinib in patients with SSc-associated in...
Autores principales: | Martyanov, Viktor, Kim, Grace-Hyun J., Hayes, Wendy, Du, Shuyan, Ganguly, Bishu J., Sy, Oumar, Lee, Sun Ku, Bogatkevich, Galina S., Schieven, Gary L., Schiopu, Elena, Marangoni, Roberta Gonçalves, Goldin, Jonathan, Whitfield, Michael L., Varga, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679625/ https://www.ncbi.nlm.nih.gov/pubmed/29121645 http://dx.doi.org/10.1371/journal.pone.0187580 |
Ejemplares similares
-
Drug‐induced interstitial lung disease associated with dasatinib coinciding with active tuberculosis
por: Tani, Nozomi, et al.
Publicado: (2020) -
Dasatinib-induced Nonspecific Interstitial Pneumonia That Developed 7 Years after the Initiation of Dasatinib
por: Takekoshi, Daisuke, et al.
Publicado: (2020) -
Safety and Tolerability of Thrombin Inhibition in Scleroderma‐Associated Interstitial Lung Disease
por: Silver, R. M., et al.
Publicado: (2019) -
The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects
por: Bogatkevich, Galina S., et al.
Publicado: (2012) -
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
por: Li, Jiannong, et al.
Publicado: (2010)